However, in EGFR-mutant NSCLC cell lines (HCC827 and H1650), EGFR and CXCR7 expression substantially decreased after longer treatment (three and seven days) with gefitinib in a dose-dependent manner (Figure 6b). Here, ACKR3 is linked to non-small cell lung carcinoma.